StreetInsider.com News Articles

Form 6-K EUDA Health Holdings For: Jun 01

Mon, 01 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260601/26579867.html

Form 6-K EUDA Health Holdings For: Jun 01

Mon, 01 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260601/26579867.html

Form 6-K EUDA Health Holdings For: May 31

Mon, 01 Jun 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260601/26579227.html

Form 6-K EUDA Health Holdings For: May 31

Mon, 01 Jun 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260601/26579227.html

EUDA Health launches new skincare mask in Helixé product expansion

Mon, 01 Jun 2026 06:08:21 -0400

EUDA Health Holdings Limited (NASDAQ: EUDA) announced the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, expanding its Helixé product line. The Singapore-based healthcare provider developed the beauty product through Chemokine Pte Ltd, a biotech company focused on molecular supplements.

EUDA holds exclusive global distribution rights for Helixé products from Chemokine. The new mask uses iPSC-derived skin stem cell secretome technology and cellulose mask technology designed to support skin hydration, brightening, and recovery.

The global face mask market was valued at approximately $7.95 billion in 2026 and is forecast to reach $9.08 billion by 2031, according to Mordor Intelligence's Face

EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

Mon, 01 Jun 2026 06:05:00 -0400

SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced it is expanding the Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask (“Regenixé Mask”), a beauty product developed by Chemokine Pte Ltd (“Chemokine”).

EUDA holds the exclusive global distributorship rights for Helixé products, that includes but is not limited to, a next-generation immune health supplement, from Chemokine, a Singapore-based biotech company focused on molecular supplements

EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

Mon, 01 Jun 2026 06:05:00 -0400

EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

Mon, 01 Jun 2026 06:05:00 -0400

EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

Mon, 01 Jun 2026 06:05:00 -0400

EUDA Health regains Nasdaq compliance after market value recovery

Mon, 01 Jun 2026 06:00:14 -0400

EUDA Health Holdings Limited (NASDAQ: EUDA) announced it has regained compliance with Nasdaq listing requirements after its market value of listed securities exceeded the minimum threshold for 10 consecutive business days.

The Singapore-based healthcare provider received notice from Nasdaq on April 23, 2026, stating it had failed to maintain the required minimum market value of listed securities of $35 million over 32 consecutive business days, as mandated by Nasdaq Listing Rule 5550(b)(2).

On May 28, 2026, Nasdaq notified EUDA that its market value had been $35 million or greater for 10 consecutive business days from May 13 to May 27, 2026, restoring

EUDA Health regains Nasdaq compliance after market value recovery

Mon, 01 Jun 2026 06:00:14 -0400

On May 28, 2026, Nasdaq notified EUDA that its market value had been $35 million or greater for 10 consecutive business days from May 13 to May 27, 2026, restoring

EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Mon, 01 Jun 2026 06:00:00 -0400

Singapore, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities (“MVLS”) of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2).

On May 28, 2026, the Company received a written

EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Mon, 01 Jun 2026 06:00:00 -0400

On May 28, 2026, the Company received a written

EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Mon, 01 Jun 2026 06:00:00 -0400

On May 28, 2026, the Company received a written

EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Mon, 01 Jun 2026 06:00:00 -0400

On May 28, 2026, the Company received a written

Form F-3 EUDA Health Holdings

Tue, 26 May 2026 11:46:00 -0400

si-local-file:///var/storage/secattach/20260526/26548231.html

Form F-3 EUDA Health Holdings

Tue, 26 May 2026 11:46:00 -0400

si-local-file:///var/storage/secattach/20260526/26548231.html

Form 6-K EUDA Health Holdings For: Apr 28

Tue, 28 Apr 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260428/26385698.html

Form 6-K EUDA Health Holdings For: Apr 28

Tue, 28 Apr 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260428/26385698.html

Form 20-F EUDA Health Holdings For: Dec 31

Tue, 28 Apr 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260428/26384706.html

Form 20-F EUDA Health Holdings For: Dec 31

Tue, 28 Apr 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260428/26384706.html

EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

Tue, 28 Apr 2026 06:00:00 -0400

SINGAPORE, April 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced that Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of cellular therapies in China, has received official approval under the 2025 Shenzhen Key Industry R&D Program.

The Shenzhen Key Industry R&D Program is a government-run initiative designed to support critical technological innovation and industrial development. The approved project is scheduled to be implemented from January 1, 2026, to December 31, 2028, under

EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

Tue, 28 Apr 2026 06:00:00 -0400

EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

Tue, 28 Apr 2026 06:00:00 -0400

EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

Tue, 28 Apr 2026 06:00:00 -0400